Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non –Small Cell Lung Carcinoma

This study validates a blood-based genome-testing service that provides accurate results within 72 hours. We focused on targetable variants in advanced non –small cell lung carcinoma—epidermal growth factor receptor gene (EGFR) variant L858R, exon 19 deletion (ΔE746−A750), and T790M; GTPase Kirsten ras gene (KRAS) variants G12C/D/V; and echinoderm microtubule associated protein like and 4 anaplastic lymphoma receptor tyrosine kinase fusion (EM L4-ALK) transcripts 1/2/3.

http://jmd.amjpathol.org/article/S1525-1578(17)30094-6/fulltext?rss=yes

Source: Journal of Molecular Diagnostics - April 19, 2017 Category: Pathology Authors: Hestia Mellert, Trudi Foreman, Leisa Jackson, Dianna Maar, Scott Thurston, Kristina Koch, Amanda Weaver, Samantha Cooper, Nicholas Dupuis, Ubaradka G. Sathyanarayana, Jakkie Greer, Westen Hahn, Dawne Shelton, Paula Stonemetz, Gary A. Pestano Tags: Regular article Source Type: research